Mises à jour récentes
-
Advancing Drug Development: Strategies for Prolonging Drug Half-LifeThe realm of biopharmaceuticals plays a crucial role in modern medical treatment, yet faces significant challenges. A notable concern is the brief half-life of many biopharmaceutical products, leading to swift degradation and clearance from the patient's body, necessitating frequent dosing. This article delves into the ways in which half-life extension strategies in drug development can...0 Commentaires 0 Parts 89 Vue 0 AperçuConnectez-vous pour aimer, partager et commenter!
-
Stroke Cats Happily and Stay Away from AllergiesFor cat lovers, the most tragic thing is probably the cat allergy. As soon as you get close to the cat, you sneeze, have a runny nose, or itchy eyes, skin rashes, and even asthma attacks. There are many people who are allergic to cats, with about 1 in 10 in the population. In some areas, as many as 30% of the population are allergic to cats. While enduring allergies, there are many cat...0 Commentaires 0 Parts 85 Vue 0 Aperçu
-
Dissecting the Alternative Splicing mechanism of influenza virus: a new host-targeted antiviral strategyInfluenza A Virus (IAV) is one of the most important causes of respiratory infections and has caused tens of millions of deaths in several pandemic outbreaks throughout human history. In recent years, the recurrence of influenza epidemics in poultry and swine flocks has posed a serious threat to public health safety, thus, research on the prevention, control, and treatment of influenza viruses...0 Commentaires 0 Parts 76 Vue 0 Aperçu
-
Which mRNA Vaccine Works Better Over Time?The continued emergence of SARS-CoV-2 variants and breakthrough infections following vaccination underscore the need to study the effectiveness of current COVID-19 vaccines in the real world. To date, only two mRNA COVID-19 vaccines have been approved for marketing, mRNA-1273 developed by Moderna and BNT162b2 developed by Pfizer/BioNTech, which have proven to be very effective in preventing...0 Commentaires 0 Parts 144 Vue 0 Aperçu
Plus de lecture